Policosanol is ineffective in the treatment of hypercholesterolemia: A randomized controlled trial

American Journal of Clinical Nutrition

Volumn 84, Issue 6, 2006, Pages 1543-1548

  Dulin, Michael F ^a,d   Hatcher, Lauren F ^b   Sasser, Howell C ^c   Barringer, Thomas A ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b Center for Cardiovascular Health   (United States)

^c R Stuart Dickson Institute for Health Studies   (United States)

^d NONE   (United States)

Author keywords

Aliphatic alcohols; Cholesterol; HDL; LDL; Nuclear magnetic resonance spectroscopy; Policosanol

Indexed keywords

ANTIALLERGIC AGENT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALTODEXTRIN; MULTIVITAMIN; OCTA 60; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; UNSPECIFIED SIDE EFFECT;

SACCHARUM;

EID: 33845496494     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.6.1543     Document Type: Article

References (41)

1. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002;143:356-65.
2. Kahn T. Over the counter supplements for cholesterol lowering. Pharmacist's/Prescriber's Letter 2006;22:220105.
3. Bayer One-A-Day Cholesterol Plus. Internet: http://www.one-a-day.com/ products/cholesterol.shtml (accessed 4 July 2006).
4. Noa M, Mas R, Mesa R. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery. Pharmacol Res 2001;43:31-7.
5. Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003;20:153-63.
6. Mas R, Castano G, Fernandez J, et al. Long-term effects of policosanol on older patients with Type 2 diabetes. Asia Pac J Clin Nutr 2004;13(suppl):S101.
7. Head KA, ed. Policosanol monograph. Sandpoint, ID: Thorne Research Inc, 2004;9:312-7.
8. Castano G, Fernandez L, Mas R, et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D 2005;6:207-19.
9. Mas R, Castano G, Fernandez J, et al. Long-term effects of policosanol on obese patients with Type II Hypercholesterolemia. Asia Pac J Clin Nutr 2004;13(suppl):S102.
10. Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002;22:89-99.
11. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez E. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3:159-72.
12. Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001;21:43-57.
13. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001;56:M186-92.
14. Menendez R, Mas R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000;50:255-62.
15. Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;14:187-95.
16. Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65:439-47.
17. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non-insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999;19:117-27.
18. Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999;19:105-16.
19. Varady KA, Wang Y, Jones PJ. Role of policosanols in the prevention and treatment of cardiovascular disease. Nutr Rev 2003;61:376-83.
20. McCarty MF. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen. Med Hypotheses 2002;59:268-79.
21. Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001;32:8-12.
22. Janikula M. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 2002;7:203-17.
23. Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 2006;95:968-75.
24. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006;295:2262-9.
25. Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004;53:1309-14.
26. Wang YW, Jones PJ, Pischel I, Fairow C. Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids 2003;38:165-70.
27. Murphy KJ, Saint DA, Howe PR. Lack of effect of sugar cane and sunflower seed policosanols on plasma cholesterol in rabbits. Asia Pac J Clin Nutr 2004;13(suppl):S69.
28. Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-Wild S, Connor WE. The Diet Habit Survey: a new method of dietary assessment that relates to plasma cholesterol changes. J Am Diet Assoc 1992;92:41-7.
29. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002;48:171-80.
30. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992;38:1632-8.
31. Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 2002;22:55-66.
32. Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32.
33. Batista J, Stusser R, Saez F, Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 1996;34:134-7.
34. Torres O, Agramonte AJ, Illnait J, Mas Ferreiro R, Fernandez L, Fernandez JC. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-7.
35. Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15:159-65.
36. Prat H, Roman O, Pino E. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]. Rev Med Chil 1999;127:286-94 (in Spanish).
37. Nikitin IuP, Slepchenko NV, Gratsianskii NA, et al. [Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia]. Ter Arkh 2000;72:7-10 (in Russian).
38. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005;25:171-83.
39. Reiner Z, Tedeschi-Reiner E, Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolemic patients. Clin Drug Invest 2005;25:701-7.
40. Tedeschi-Reiner E, Reiner Z, Romic Z, Ivankovic D. [A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia]. Lijec Vjesn 2005;127:273-9 (in Croatian).
41. Fong RL, Ward HJ. The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Am J Med 1997;102:387-91.